FindMyKOL
Clinical trialNCT06175000RecruitingPhase 2Interventional

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

SponsorProvidence Health & ServicesEnrollment28Primary Central Nervous System Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Christian Grommes, MD
    Recruiting
  • Cleveland Clinic

    Cleveland, Ohio, United States

    Withdrawn
  • Providence Health & Services; Providence Neurological Specialties

    Portland, Oregon, United States

    Prakash Ambady, MD
    Recruiting
  • Pennsylvania State University

    Hershey, Pennsylvania, United States

    Dawit Aregawi, MD
    Recruiting
  • University of Vermont

    Burlington, Vermont, United States

    Alissa Thomas, MD
    Recruiting
  • University of Virginia

    Charlottesville, Virginia, United States

    David Schiff, MD
    Recruiting
  • Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute

    Seattle, Washington, United States

    Alipi Bomn, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Obinutuzumab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Mar 2024
Primary completion
15 Sept 2028
Completion
15 Sept 2029
Last update posted
23 Sept 2026
Registered enrollment
28
Registry id
NCT06175000
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.